

Brilliant Violet 650™ anti-mouse CD86

Catalog # / Size: 1125175 / 125 µl
1125180 / 50 µg

Clone: GL-1

Isotype: Rat IgG2a, κ


Immunogen: LPS-activated CBA/Ca mouse splenic B cells

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 650™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



LPS-stimulated (3 days) C57BL/6 mouse splenocytes were stained with GL-1 Brilliant Violet 650™.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 µL per million cells or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The GL-1 antibody can block the mixed lymphocyte reaction *in vitro* and has been shown to inhibit the priming of cytotoxic T lymphocytes *in vivo* (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation¹, immunohistochemical staining of acetone-fixed frozen sections^{2,6}, immunofluorescence microscopy, and *in vivo* and *in vitro* blocking of T cell responses¹⁻⁶. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105010).

- Application** 1. Hathcock KS, *et al.* 1993. *Science* 262:905. (Block, IP)
- References:** 2. Inaba KM, *et al.* 1994. *J. Exp. Med.* 180:1849. (Block, IHC)
3. Hathcock KS, *et al.* 1994. *J. Exp. Med.* 180:631. (Block)
4. Krummel MF, *et al.* 1995. *J. Exp. Med.* 182:459. (Block)
5. Liu Y, *et al.* 1997. *J. Exp. Med.* 185:251. (Block)
6. Herold KC, *et al.* 1997. *J. Immunol.* 158:984. (Block, IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
9. Turnquist HR, *et al.* 2007. *J. Immunol.* 178:7018.
10. Klinger MB, *et al.* 2007. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 293:R677.
[PubMed](#)
-

Description: CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

- Antigen** 1. Barclay A, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
- References:** 2. Hathcock KS, *et al.* 1993. *Science* 262:905.
3. Freeman GJ, *et al.* 1993. *Science* 262:907.
4. Carreno BM, *et a*